Biodegradable Implant Buffering Agent pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bioabsorbable medical devices, particularly those for vascular and cardiovascular applications, face challenges in controlling the acidic effects of degradation, which can lead to local tissue inflammation due to the release of acidic byproducts during polymer breakdown, lacking effective self-regulating systems to mitigate these issues.
Innovation Solution
A biodegradable and/or bioabsorbable medical device with structural components made of or coated with a first biodegradable material, incorporating a second biodegradable material that encapsulates a buffering agent, which is released in response to hydrolysis to neutralize acidic environments and maintain pH levels within a safe range, potentially including therapeutic agents for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If bulk eroding polymeric materials are used for bioabsorbable implants, then the implants can provide structural support and be resorbable, but acidic byproducts are released during degradation causing local tissue inflammation
Solution Approach 1:
A buffering agent is introduced as an intermediary substance that mediates between the acidic degradation byproducts and the surrounding tissue. The buffering agent neutralizes the acid fragments released during polymer degradation, preventing direct contact with tissue and thereby eliminating the inflammatory response while maintaining the structural integrity of the bulk eroding polymer implant
Solution Approach 2:
The harmful acidic byproducts generated during polymer degradation are converted into a beneficial neutralization process. The buffering agent transforms the acidic environment into a neutral pH condition, converting the harmful acid fragments into harmless neutralized products that do not cause tissue inflammation
2Object-affected harmful factors
If surface eroding polymers are used, then tissue inflammation is reduced due to small acid release, but the structural support and resorbability characteristics are limited
Solution Approach 1:
The invention merges the advantages of both bulk eroding and surface eroding polymers by combining a bulk eroding polymeric material with a buffering agent. This combination allows the implant to maintain structural support through bulk erosion while the buffering agent prevents tissue inflammation by neutralizing released acids, effectively merging the structural benefits of bulk erosion with the biocompatibility benefits of surface erosion
3Reliability
If biodegradable materials are used for vascular devices, then biocompatibility can be improved, but acidic degradation products cause pH drops and inflammation
Solution Approach 1:
The buffering agent provides self-service functionality within the implant system by automatically neutralizing acidic byproducts as they are released during degradation. This self-regulating mechanism maintains pH balance without requiring external intervention, ensuring continuous biocompatibility throughout the degradation process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device effectively suppresses inflammation and maintains pH levels within a physiologically safe range, reducing tissue reaction and ensuring the biocompatibility of the device by neutralizing acidic byproducts, thereby enhancing the biocompatibility and therapeutic efficacy.
Implementation Method 1
incorporating a buffering agent, which is released in response to hydrolysis to neutralize acidic environments and maintain pH levels within a safe range
Implementation Method 2
the buffering agent, which is released in response to hydrolysis of the biodegradable material
Data Source
AI summary
A medical device for placement at a site in a patient's body and for controlling pH levels at the site in the patient's body includes one or more structural components made of a first biodegradable and/or bioabsorbable material or, alternatively, one or more structural components having a coating thereon made of a first biodegradable and/or bioabsorbable material. The device also includes a buffering agent and at least one second biodegradable and/or bioabsorbable material on or in the one or more structural components, or alternatively, on or in the coating on the one or more structural components. The at least one second biodegradable and/or bioabsorbable material encapsulates the buffering agent and the buffering agent is dispersed from the at least one second biodegradable and/or bioabsorbable material in response to hydrolysis of the first biodegradable and/or bioabsorbable material. Additionally, the device can include a drug that is either also encapsulated by the at least one second biodegradable and/or bioabsorbable material or is included with the first biodegradable and/or bioabsorbable material.